Neurology · Major Depressive DisorderTrial Updateclinicalmid-term

Neurocrine's NBI-1065845 Shows Promise as Adjunctive Treatment for Major Depressive Disorder

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 12:31:37 PM

Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The ongoing trial of NBI-1065845 as an adjunctive treatment for Major Depressive Disorder could significantly impact Neurocrine's competitive positioning in the neurology market. Success in this trial may address unmet needs for patients not fully responding to current therapies, influencing future development strategies. Regulatory context from MHRA (ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly) supports the near-term read. Assessment grounded in 17 ranked evidence items (7 high-relevance).

Strategic Assessment

The strongest clinical anchor is NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) (ClinicalTrials.gov), entity match (neurocrine biosciences). In Neurology · Major Depressive Disorder, 4 regulatory and 2 competitive items passed relevance filtering for Neurocrine Biosciences. If NBI-1065845 proves effective, it could capture market share from existing depression treatments, potentially leading to increased revenue for Neurocrine.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche).

Regulatory Outlook

Regulatory risk is concentrated around ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly (MHRA). Regulatory pathway relevance (nda). Relevant agencies in corpus: MHRA, FDA. The outcomes of this trial will be critical for regulatory approval processes, as they will determine the safety and efficacy profile necessary for market entry.

Key Risks

Elevated medium regulatory exposure for Neurocrine Biosciences could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If NBI-1065845 proves effective, it could capture market share from existing depression treatments, potentially leading to increased revenue for Neurocrine.
Upside for Neurocrine Biosciences may improve if Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) (ClinicalTrials.gov) delivers favorable follow-through.
The potential of NBI-1065845 to fill treatment gaps in Major Depressive Disorder, impacting future development strategies.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly
MHRAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves First Single-Dose Generic Treatment for Influenza
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Lower dose needle-free allergy treatment approved for younger children
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
Over-The-Counter (OTC) Heartburn Treatment
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
ClinicalTrials.govhigh relevance
Entity match (neurocrine biosciences)
FDA document
View source
Trial of an Online Spanish Pivotal Response Treatment Training in Autism Spectrum Disorder
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Developing and Testing Innovative Care Pathways for Screening and Treatment of OUD/PTSD in Jails
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schiz
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and tolerability of linezolid as an adjunctive treatment for nontuberculous mycobacterial infections in patients with adult-onset immunodeficiency syndrome: a prospective cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Observation of the therapeutic effect of flunarizine capsules combined with the Epley manoeuvre in the treatment of benign paroxysmal positional vertigo.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Neurocrine Biosciences
NBI-1065845
Major Depressive Disorder market

Commercial impact

medium

If NBI-1065845 proves effective, it could capture market share from existing depression treatments, potentially leading to increased revenue for Neurocrine.

Regulatory impact

medium

The outcomes of this trial will be critical for regulatory approval processes, as they will determine the safety and efficacy profile necessary for market entry.

What to watch

Monitor trial results and any announcements regarding efficacy and safety outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.